 If you are found to be eligible to take part in this study, you will be assigned to a dose level of temsirolimus and dasatinib based on when you join this study. Up to 2 dose levels of both drugs will be tested. Up to 6 participants will be enrolled in each group. The first group of participants will receive the lowest dose level of both drugs. If no intolerable side effects are seen, the next group will receive a higher dose level of temsirolimus. If no intolerable side effects are seen in this second group, the third group will receive the higher dose level of temsirolimus and a higher dose level of dasatinib. 